Every Form 4 that PROCEPT BioRobotics Corporation (PRCT) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow PRCT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PRCT filings page.
PROCEPT BioRobotics Corp (PRCT) executive Alaleh Nouri, EVP, CLO and Corporate Secretary, reported a small sale of common stock primarily for tax purposes. On September 9, 2026, 297 shares were sold at $20.953 per share under the company’s sell-to-cover process tied to RSU vesting. Following this tax-withholding sale, Nouri directly holds 127,737 shares of PROCEPT BioRobotics common stock.
PROCEPT BioRobotics Corp (PRCT) reported that executive vice president and chief technology officer Barry L. Templin sold 373 shares of common stock on September 9, 2026 at $20.95 per share. According to the company, the sale was made under its sell-to-cover process to satisfy tax withholding on restricted stock units that vested on September 5, 2026. Following this tax-related sale, Templin directly holds 94,826 shares of PROCEPT BioRobotics common stock.
PROCEPT BioRobotics Corp (PRCT) reported an insider transaction by Kevin Waters, EVP and CFO. On September 9, 2026, he sold 373 shares of common stock at $20.953 per share in an open-market or private transaction pursuant to the company’s sell-to-cover tax withholding process, and continued to hold 180,355 shares directly afterward.
PROCEPT BioRobotics Corp executive Nouri Alaleh reported equity compensation awards on August 13, 2026. He received 22,965 shares of Common Stock in the form of restricted stock units (RSUs), each representing one share, increasing his direct Common Stock holdings to 128,034 shares after the grant.
Alaleh was also granted a Stock Option for 31,773 shares of Common Stock at an exercise price of $21.95 per share, expiring on August 12, 2036, bringing his directly held stock options from this grant to 31,773. The RSUs vest 25% on August 13, 2027, with the remaining three-quarters vesting quarterly over 36 months, while 1/48th of the option shares vest monthly from August 13, 2026 over four years, in each case subject to continued service. Both awards are intended to represent 50% of the value of his expected 2027 grant, made in lieu of that portion of the future grant.
PROCEPT BioRobotics Corp reported compensation-related equity awards to EVP and Chief Technology Officer Barry L. Templin. On August 13, 2026, he received a grant of 36,312 stock options with an exercise price of $21.95 per share, expiring on August 12, 2036. These options vest 1/48 monthly starting August 13, 2026, over four years, subject to continued service.
On the same date, he was also granted 26,246 restricted stock units (RSUs), each representing one share of common stock. One-quarter of the RSUs vest on August 13, 2027, with the remainder vesting quarterly over 36 months, contingent on continued service. Following the RSU grant, he directly holds 95,199 common shares. Both awards are intended to represent 50% of the value of his expected 2027 grant and are made in lieu of that portion.
PROCEPT BioRobotics Corp reports that EVP and CFO Kevin Waters received equity awards on August 13, 2026. He was granted 29,527 RSUs, each representing a contingent right to one share of common stock, bringing his directly held common shares to 180,728. He also received a stock option for 40,851 shares of common stock at an exercise price of $21.95 per share, expiring on August 12, 2036, with 40,851 option shares outstanding after the grant.
The RSUs vest with one-quarter on August 13, 2027 and the remainder in equal quarterly installments over 36 months, subject to continued service. The option vests in 1/48th monthly installments starting August 13, 2026 over four years, also subject to continued employment or service. Both awards are intended to represent 50% of the value of Waters’ expected 2027 grant, in lieu of that portion of the 2027 award.
PROCEPT BioRobotics Corp reported that Chief Strat/Marketing Officer Pooja Sharma received equity awards on August 13, 2026. She was granted 23,622 restricted stock units, each representing one share of common stock, and a stock option for 32,681 shares at an exercise price of $21.95 per share, expiring August 12, 2036.
The RSUs vest 25% on August 13, 2027, with the remainder vesting quarterly over 36 months, subject to continued service. The option vests in equal monthly installments over four years starting August 13, 2026. Both grants are intended to represent 50% of the value of Sharma’s expected 2027 grant, made in lieu of that portion. Following these awards, she directly holds 111,181 shares of common stock.
PROCEPT BioRobotics Corp reported that President and CEO Larry L. Wood, through The Larry Wood Trust, purchased 23,900 shares of common stock on August 7, 2026 at a weighted average price of $20.85 per share, with individual trade prices ranging from $20.67 to $21.02. Following this transaction, the trust holds 23,900 shares indirectly, and Wood also holds 314,203 shares directly, which include 825 shares acquired on May 14, 2026 under the company’s 2021 Employee Stock Purchase Plan.
PROCEPT BioRobotics director Antal Rohit Desai received new equity awards as compensation. He was granted 3,315 restricted stock units, each representing one future share of Common Stock, increasing his reported Common Stock holdings to 38,467 shares. He also received a stock option for 5,853 shares at an exercise price of $28.78 per share. Both the RSUs and the option vest in full on the earlier of the one-year anniversary of the June 9, 2026 grant date or the next annual meeting following that date, subject to his continued service.
PROCEPT BioRobotics Corp director Amy M. Dodrill received equity-based compensation consisting of restricted stock units and stock options. She was granted 3,315 restricted stock units, each representing one share of common stock, increasing her direct common share holdings to 10,941 shares after the grant.
Dodrill was also granted 5,853 stock options with an exercise price of 28.78 per share, all of which remain outstanding and expire on June 8, 2036. Both the RSUs and options vest in full on the earlier of the one-year anniversary of the June 9, 2026 grant date or the next annual meeting following that date, subject to her continued service.
PROCEPT BioRobotics director Mary Garrett received new equity awards. She was granted 3,315 restricted stock units, bringing her direct common stock holdings to 17,700 shares after the award. She also received a stock option for 5,853 shares at an exercise price of $28.78, expiring on June 8, 2036.
Both the RSUs and the option vest in full on the earlier of the one-year anniversary of the June 9, 2026 grant date or the next annual meeting, if she continues serving until that vesting date.
PROCEPT BioRobotics director Taylor C. Harris received new equity awards as part of director compensation. He was granted 3,315 restricted stock units, each representing one share of Common Stock, and 5,853 stock options with an exercise price of $28.78 per share. Both the RSUs and options vest in full on the earlier of the one-year anniversary of the June 9, 2026 grant date or the next annual meeting, subject to continued service. After this award, Harris directly holds 102,491 shares of Common Stock.
PROCEPT BioRobotics Corp director Elisabeth Sandoval received new equity compensation awards. On June 9, 2026, she was granted 3,315 restricted stock units (RSUs), each representing one share of common stock, and stock options for 5,853 shares at an exercise price of $28.78 per share.
The RSUs and options vest in full on the earlier of the one-year anniversary of the grant date or the next annual meeting, subject to her continued service. After the RSU grant, Sandoval directly owns 15,876 shares of common stock. The newly granted options expire on June 8, 2036.
PROCEPT BioRobotics Corp director Frederic H. Moll received new equity awards as part of his compensation. He acquired 3,315 restricted stock units, each representing one future share of common stock, which will vest in full on the earlier of the one-year anniversary of the grant date or the next annual meeting, subject to continued service.
He was also granted a stock option for 5,853 shares of common stock at an exercise price of $28.78 per share, vesting on the same schedule. Following the RSU award, Moll directly holds 866,474 shares of common stock, indicating this is a routine, compensation-related equity grant rather than an open-market purchase or sale.
PROCEPT BioRobotics director Thomas M. Prescott received new equity awards in the form of restricted stock units and stock options. He was granted 3,315 restricted stock units, each representing a right to receive one share of Common Stock, and now holds 7,211 shares of Common Stock following the award. The RSUs vest in full on the earlier of the one-year anniversary of the June 9, 2026 grant date or the next annual meeting, subject to continued service.
He was also granted stock options for 5,853 shares of Common Stock at an exercise price of $28.78 per share, vesting on the same schedule and expiring on June 8, 2036. These are compensation-related grants rather than open‑market purchases or sales.
PROCEPT BioRobotics director Dan Puckett received new equity awards. He was granted 3,315 restricted stock units, each representing a right to one share of common stock, increasing his direct common stock holdings to 8,791 shares after the grant.
He was also granted stock options for 5,853 shares of common stock at an exercise price of $28.78 per share, expiring on June 8, 2036. Both the RSUs and options vest in full on the earlier of one year from the June 9, 2026 grant date or the next annual meeting, subject to continued service.
PROCEPT BioRobotics Corp executive sells small number of shares for tax withholding. EVP and Chief Legal Officer Nouri Alaleh sold 285 shares of common stock at an average price of $28.48 per share in an open‑market transaction.
According to the footnote, this sale was executed under the company’s sell‑to‑cover process to satisfy tax obligations related to restricted stock units that vested on June 5, 2026. After the transaction, Alaleh directly holds 105,069 shares of PROCEPT BioRobotics common stock, so the sale represents a very small portion of his overall holdings.
PROCEPT BioRobotics EVP and CFO Kevin Waters reported a small sale of 357 shares of common stock. The shares were sold on June 8, 2026 at an average price of $28.479 per share. According to the filing, the sale was made through the company’s sell-to-cover process to satisfy tax withholding obligations tied to Restricted Stock Units that vested on June 5, 2026. After this transaction, Waters directly owns 151,201 shares, indicating the sale was minor relative to his overall holdings.
PROCEPT BioRobotics EVP and CTO Barry L. Templin reported a small sale of 358 shares of Common Stock on June 8, 2026 at $28.479 per share. According to the footnotes, this transaction was executed under the company’s sell-to-cover process to satisfy tax withholding obligations related to Restricted Stock Units that vested on June 5, 2026, indicating it was a routine tax-driven event rather than a discretionary sale. After this transaction, Templin directly holds 68,953 shares of PROCEPT BioRobotics common stock. The footnotes also note that his holdings include 860 shares acquired on May 14, 2026 through the company’s 2021 Employee Stock Purchase Plan.
PROCEPT BioRobotics Corp executive vice president and chief legal officer Alaleh Nouri reported selling a total of 5,363 shares of common stock in two open‑market transactions. The shares were sold at weighted average prices of $25.8193 for 3,031 shares and $26.1460 for 2,332 shares.
The filing states these sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on June 4, 2025. After the transactions, Nouri directly holds 105,354 shares, indicating the sales represent a relatively small portion of her overall position.
PROCEPT BioRobotics Corp executive reports small share sale tied to tax withholding. EVP, Chief Legal Officer and Corporate Secretary Alaleh Nouri sold 304 shares of common stock at an average price of $28.1532 per share. According to the footnote, the sale was made solely to cover tax withholding obligations from the vesting of restricted stock units, rather than as a discretionary open-market transaction. After this sale, Nouri directly holds 110,717 shares of PROCEPT BioRobotics common stock, indicating the transaction is minor relative to her overall stake.
PROCEPT BioRobotics Corp EVP and CFO Kevin Waters reported a small insider transaction involving company common stock. On March 17, 2026, he sold 706 shares at an average price of $28.1532 per share. According to the footnote, these shares were sold specifically to cover tax withholding obligations tied to the vesting of Restricted Stock Units, making this a routine, compensation-related event rather than a discretionary sale. After the transaction, Waters still directly owns 151,558 shares of PROCEPT BioRobotics common stock.
PROCEPT BioRobotics EVP, CLO and Corporate Secretary Alaleh Nouri sold 3,243 shares of common stock in open-market transactions. The sales on March 10, 2026 occurred at weighted average prices of $25.6037 and $26.7379 per share under a Rule 10b5-1 trading plan adopted on June 4, 2025. Following these transactions, Nouri directly holds 111,021 shares of PROCEPT BioRobotics common stock.
PROCEPT BioRobotics Corp director-linked entity Kestrel Fund, L.P. reported open-market purchases of 426,262 shares of common stock over several days. The buys occurred on March 5, 6 and 9, 2026 at weighted average prices generally between the low $20s and mid $20s per share, as detailed in price ranges in the footnotes. The filing also shows 35,152 shares held directly and 14,363 shares held indirectly by The 2:22 DNA Trust as of March 5, 2026. Antal Rohit Desai, a director and managing partner of CPMG, Inc., may be deemed to share voting and investment power over Kestrel Fund holdings but disclaims beneficial ownership except to the extent of any pecuniary interest.
PROCEPT BioRobotics President and CEO Larry L. Wood received equity awards on March 5, 2026. He was granted 103,653 stock options at an exercise price of $0.00 per share and 127,783 restricted stock units (RSUs) of common stock.
The RSUs vest over four years, with one-quarter vesting on March 5, 2027 and the remainder vesting quarterly over 36 months, conditioned on continued service. The stock options vest monthly over four years from March 5, 2026, also subject to continued employment or service.
PROCEPT BioRobotics EVP, CLO and Corporate Secretary Nouri Alaleh reported mixed equity transactions. On March 6, 2026, Alaleh sold 6,892 shares of Common Stock at an average price of $23.7019, with the shares sold to cover tax withholding obligations tied to vesting of restricted and performance stock units. Following this sale, direct ownership of Common Stock was 114,264 shares.
On March 5, 2026, Alaleh received 43,811 shares of Common Stock as a grant, structured as restricted stock units that vest over four years, beginning with one-quarter on March 5, 2027, and the remainder in quarterly installments. Alaleh was also granted a stock option for 29,615 shares, vesting in equal monthly installments over four years starting March 5, 2026, contingent on continued service.
PROCEPT BioRobotics EVP & CFO Kevin Waters reported a mix of equity awards and a tax-related share sale. On March 5, he received 47,462 restricted stock units and a stock option for 32,576 shares, both at no cash cost, with multi‑year vesting starting in March 2026–2027.
On March 6, he sold 6,721 shares of common stock at an average price of $23.7019 per share to cover tax withholding obligations tied to vesting RSUs and performance stock units. After the sale, he directly held 152,264 shares of common stock.
PROCEPT BioRobotics Corp director Dan Puckett received new equity awards. On March 5, 2026, he was granted stock options for 8,897 shares at an exercise price of $0.00 per share and 5,476 shares of common stock in the form of restricted stock units.
One-third of the stock options and one-third of the RSUs are scheduled to vest on March 5, 2027, with the remaining two-thirds of each award vesting in equal annual installments over the following two years, subject to his continued service with the company.
PROCEPT BioRobotics Corp executive receives stock from performance award
EVP and Chief Legal Officer Nouri Alaleh acquired 4,872 shares of PROCEPT BioRobotics common stock through a grant at a price of $0.00 per share. After this award, Alaleh directly holds 77,345 common shares.
The shares represent common stock underlying a portion of previously granted performance stock units. The company’s Compensation Committee certified on February 19, 2026 that required performance goals were achieved, causing these units to be deemed earned. The earned shares are scheduled to vest on March 5, 2026, with each unit corresponding to one share of common stock.
Waters Kevin reported acquisition or exercise transactions in this Form 4 filing.
PROCEPT BioRobotics Corp EVP and CFO Kevin Waters was granted 3,532 shares of common stock through earned performance stock units. The Form 4 shows these shares at a price of $0.0000 per share, reflecting an award rather than an open-market purchase or sale.
The award represents a portion of previously granted performance stock units that became earned after the compensation committee certified achievement of preset performance goals on February 19, 2026. These earned units are scheduled to vest on March 5, 2026, and each unit corresponds to one share of common stock, bringing Waters’ direct holdings to 111,523 shares after the transaction.